Giulia Martini

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer

Erika Martinelli, Giulia Martini, Vincenzo Famiglietti et al. · JAMA Oncology · 2021 · 185 citations · Full text

Medicine, Oncology, Pharmacology +17

EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer

Giulia Martini, Claudia Cardone, Pietro Paolo Vitiello et al. · Molecular Cancer Therapeutics · 2019 · 92 citations · Full text

Medicine, Oncology, Pharmacology +17

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi‐targeted kinase inhibitors in pimasertib‐resistant human lung and colorectal cancer cells

Erika Martinelli, Teresa Troiani, Elena D’Aiuto et al. · International Journal of Cancer · 2013 · 91 citations · Full text

Medicine, Oncology, Pharmacology +15

Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines

Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 91 citations · Full text

Medicine, Oncology, Pharmacology +17

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

Stefania Napolitano, Giulia Martini, Barbara Rinaldi et al. · Clinical Cancer Research · 2015 · 72 citations

Medicine, Oncology, Pharmacology +15